Risk factors impacting outcomes of third party virus-specific T cell therapy for refractory viral infections in children

Flow cytometry dataset from the ACES study (NCT#03475212), a phase II multicenter consortium study for the treatment of pediatric patients with inborn errors of immunity and/or post allogeneic hematopoietic stem cell transplant with refractory viral infections using partially-HLA matched virus-specific T cells targeting cytomegalovirus, Epstein-Barr virus, or adenovirus.  Recipients of virus-specific T cell infusions were evaluated at multiple time points before and after infusion, with a focus on days 0, 14, 28, 45, and 90.  Recipient T cells were expanded in vitra against the targeted viruses for 10 days and then re-stimulated with viral peptide libraries (CMV pp65/IE1, EBV EBNA1/LMP2, Adenovirus hexon/penton) and evaluated by intracellular cytokine staining.   Staining of disparate HLA alleles between the VST donor and HSCT donor was included where possible.